<DOC>
	<DOCNO>NCT01789411</DOCNO>
	<brief_summary>The AtheroRemo-IVUS study aim investigate relation coronary plaque phenotype vulnerability determine intravascular ultrasound near infrared spectroscopy genetic profile novel circulate biomarkers . AtheroRemo-IVUS prospective , observational , cohort study patient underwent coronary catheterization acute coronary syndrome stable angina pectoris . Prior catheterization procedure , blood sample draw biomarker measurement genetic analysis . Subsequent catheterization procedure , intravascular ultrasound perform non-culprit coronary artery . In patient also participate AtheroRemo-NIRS substudy , near-infrared spectroscopy additionally perform non-culprit vessel . Primary endpoint presence vulnerable plaque determine intravascular ultrasound . Secondary endpoint long-term incidence major adverse cardiac event . Results AtheroRemo-IVUS expected improve knowledge role genetic profile inflammation development atherosclerosis vulnerable plaque . Furthermore , novel biomarkers intracoronary image technique validate study .</brief_summary>
	<brief_title>The European Collaborative Project Inflammation Vascular Wall Remodeling Atherosclerosis - Intravascular Ultrasound Study</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>1 . Patients sex , 21 year old . 2 . Patients stable angina pectoris ( CCS Class 1 , 2 , 3 4 ) unstable angina pectoris ( Braunwald Class 13 , BC ) patient document silent ischemia patient acute myocardial infarction ( STEMI NSTEMI ) . 3 . Patients eligible coronary revascularization native coronary artery/arteries . 4 . Willing able comply specify followup evaluation . 5 . Written inform consent obtain . 6 . Flowlimiting stenosis ( diameter stenosis ≥50 % QCA visual estimate ) hold responsible angina pectoris acute coronary syndrome 7 . The study vessel undergone percutaneous coronary intervention last 8 month . 1 . Braunwald class IA , IIA , IIIA ( angina cause noncardiac illness ) . 2 . Women pregnant woman childbearing potential use adequate contraception . 3 . Known allergy aspirin , clopidogrel bisulfate ( Plavix ® ) , Ticlopdine ( Ticlid ® ) heparin , stainless steel , copper sensitivity contrast medium adequately premedicated . 4 . Previous participation study participation another study investigational drug device within past 30 day ( study participation end completion final followup . ) 5 . Life expectancy less one year factor make clinical and/or angiographic followup difficult . 6 . Planned status post coronary bypass surgery . 7 . Planned major noncardiac surgery . 8 . Impaired renal function ( creatinine &gt; 2 mg/dl &gt; 150 umol/L ) . 9 . The subject history bleed diathesis coagulopathy . 10 . The subject suffer disable stroke within past year . 11 . 3vessel coronary artery and/or Left main disease &gt; 50 % stenosis . 12 . Minimal lumen diameter &lt; 2mm segment analyze within study vessel . 13 . Diameter Stenosis &gt; 70 % total occlusion study vessel . 14 . In case studyvessel stented previously ( &gt; 8 month ago ) , 1/3 proximal study vessel ( least 40mm length ) available examination ( i.e. , outside length stent plus 5mm proximal stent ) . 15 . Poor LV function assess Echo Angiography . 16 . The proximal vessel moderately severely tortuous ( moderate : 2 bend &gt; 75 degree one bend &gt; 90 degree ) segment ( ) analyze . 17 . Known tendency coronary vasospasm .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>